

RESEARCH MONOGRAPH . COMPOUND PROFILE

GDF11

A TGF-beta superfamily ligand identified as a candidate circulating rejuvenation factor through heterochronic parabiosis experiments, with reported effects on cardiac hypertrophy, skeletal muscle regeneration, cerebrovascular remodeling, and neurogenesis in aged mice, now subject to significant controversy regarding assay specificity, dose-response boundaries, and translational viability.

DOCUMENT	KDC-MN-1513
ISSUED	2026-05-15
REVISION	1.0
AUTHOR	Kodi ac bio l abs Research
COMPOUND CLASS	Transforming growth factor beta superfamily secreted signaling protein (activin/myostatin subclass)

ABSTRACT

Growth differentiation factor 11 (GDF11), also designated bone morphogenetic protein 11 (BMP-11), is a secreted homodimeric signaling protein of the transforming growth factor beta (TGF-beta) superfamily that signals through activin type II receptors (ActRIIA and ActRIIB) and type I receptors ALK4 and ALK5 to activate the canonical SMAD2/3 transcription factor pathway. GDF11 shares approximately 90 percent amino acid identity in its mature signaling domain with myostatin (GDF8), the well-characterized negative regulator of skeletal muscle mass, and is regulated by the same extracellular inhibitors (follistatin, FSTL3, WFIKKN1/2) and the same tolloid-family metalloproteinase activation mechanism. The protein is synthesized as a 407-amino-acid precursor that undergoes sequential proteolytic processing: signal peptide removal, furin-mediated cleavage of the prodomain, and tolloid-dependent liberation of the active mature homodimer from the latent prodomain complex.

GDF11 became one of the most intensely debated molecules in modern aging biology following landmark publications from the laboratory of Amy Wagers and Richard Lee at Harvard between 2013 and 2014. Using heterochronic parabiosis and systemic delivery of recombinant GDF11, these investigators reported that GDF11 levels decline with age in mice and that restoration of youthful GDF11 concentrations reverses age-related cardiac hypertrophy (Loffredo et al., 2013), restores skeletal muscle stem cell function and enhances muscle repair (Sinha et al., 2014), and induces cerebrovascular remodeling with increased neurogenesis and improved olfactory discrimination in aged animals

(Katsimpardi et al., 2014). These findings generated exceptional scientific and public interest, with GDF11 described in the popular press as a circulating "youth factor" or "rejuvenation protein."

The initial claims became intensely controversial when independent laboratories demonstrated that the original immunoassays could not reliably distinguish GDF11 from its close homolog myostatin (Egerman et al., 2015; Smith et al., 2015), that circulating GDF11/myostatin immunoreactivity may increase rather than decrease with age when measured by more specific methods, and that supraphysiological recombinant GDF11 administration inhibits rather than promotes skeletal muscle regeneration and can induce severe cachexia, muscle wasting, and premature death in mice (Egerman et al., 2015; Harper et al., 2016; Hammers et al., 2017; Jones et al., 2018). These contradictory findings have not been fully resolved. The current scientific consensus recognizes GDF11 as a biologically important developmental signaling molecule with plausible but unproven therapeutic potential in aging, and regards the magnitude and direction of its age-related changes and the safety window for exogenous administration as open questions requiring further investigation with rigorously validated, myostatin-discriminating assays.

GDF11 is not approved as a therapeutic agent by any regulatory authority. Sotatercept, an ActRIIA-Fc fusion protein that sequesters GDF11 along with activin A and myostatin, was approved by the United States Food and Drug Administration in March 2024 for pulmonary arterial hypertension, representing the first clinical validation of pharmacological modulation of GDF11-class signaling. No recombinant GDF11 product has entered human clinical trials. The compound is available as a

research-grade recombinant protein from multiple commercial suppliers for in vitro and preclinical investigation. This monograph reviews the molecular biology, processing, and signaling of GDF11; the discovery and development history including the parabiosis experiments and the subsequent replication controversy; the preclinical pharmacology across cardiac, skeletal muscle, neurological, and oncological domains; the limited pharmacokinetic characterization; the sourcing, reconstitution, and quality verification considerations for research-grade material; the adverse-event and safety signal with emphasis on the cachexia and muscle-wasting toxicity at supraphysiological doses; and a structured comparative assessment of five related TGF-beta superfamily ligands and modulators against GDF11 on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Recommended name: Growth differentiation factor 11 (GDF11).

Synonyms: Bone morphogenetic protein 11 (BMP-11), GDF-11, BMP11.

Gene symbol: GDF11 (Homo sapiens), Gdf11 (Mus musculus).

Chromosomal location: 12q13.2 (human).

Online Mendelian Inheritance in Man (OMIM) entry: 603936.

UniProt accession: O95390 (GDF11_HUMAN).

GeneCards identifier: GDF11.

Chemical Abstracts Service registry number: Not assigned for the endogenous protein. Recombinant preparations are catalogued by supplier-specific identifiers (R&D Systems 1958-GD; PeproTech 120-11; Thermo Fisher 120-11).

1.2 Structural class and chemistry

GDF11 is a member of the activin/myostatin subclass of the TGF-beta superfamily of secreted signaling proteins. The superfamily is defined by the conserved cystine-knot structural motif in the mature signaling domain: seven conserved cysteine residues that form three intramolecular disulfide bonds and one intermolecular disulfide bond linking two mature-domain monomers into the biologically active homodimer [1, 2].

Precursor protein: The full-length human GDF11 precursor is a 407-amino-acid polypeptide consisting of a signal peptide (approximately residues 1 to 24), a prodomain (approximately residues 25 to 298), and a mature domain (residues 299 to 407, 109 amino acids). The prodomain contains a furin recognition motif (RSRR) at the boundary with the mature domain [3].

Mature homodimer: The biologically active form is a disulfide-linked homodimer of two 109-amino-acid chains. The molecular mass of each monomer is approximately 12.5 kilodaltons; the non-glycosylated recombinant homodimer produced in *Escherichia coli* has a molecular mass of approximately 24.9 to 25.0 kilodaltons [4, 5].

Sequence identity with myostatin: The mature domains of GDF11 and myostatin (GDF8) share approximately 90 percent amino acid sequence identity. The prodomains are only approximately 52 percent identical [6]. This high mature-domain homology is the source of the cross-reactivity in immunoassays that complicated the initial aging-biology literature.

Post-translational processing: GDF11 undergoes a sequential two-step proteolytic activation. First, furin-like proprotein convertases cleave the precursor at the RSRR motif, separating the prodomain from the mature domain. However, the cleaved prodomain remains non-covalently bound to the mature homodimer, forming a latent complex that is inactive because the prodomain shields the receptor-binding epitopes. Second, tolloid-family metalloproteinases (bone morphogenetic protein 1 [BMP1], tolloid-like 1 [TLL1], and tolloid-like 2 [TLL2]) cleave the prodomain at a specific site, destabilizing the latent complex and liberating the active mature homodimer [7, 8]. The human GDF11 latent complex is cleaved preferentially by BMP1 and TLL1.

Extracellular inhibitors: Active GDF11 is regulated in the extracellular compartment by several binding proteins that sequester the mature homodimer and prevent receptor engagement. These include follistatin (FST), follistatin-like 3 (FSTL3), WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 1 (WFIKKN1), and WFIKKN2. The prodomain itself also functions as an inhibitor when it remains bound in the latent complex [9, 10].

1.3 Synthesis and production

GDF11 is not produced by chemical synthesis. All research-grade and investigational material is recombinant protein produced by heterologous expression, predominantly in *Escherichia coli*, with refolding from inclusion bodies to generate the correctly folded, disulfide-linked homodimer. Some suppliers offer mammalian cell-expressed (CHO or HEK293) GDF11 with native glycosylation patterns, though the mature domain itself is not N-glycosylated.

E. coli-expressed recombinant human GDF11 is typically produced as the 109-amino-acid mature domain (residues 299 to 407 of the full-length precursor) and refolded as a homodimer. The protein may be supplied untagged or with an N-terminal His-tag or His-SUMO tag for affinity purification. Untagged preparations more closely approximate the native protein and are preferred for functional studies where tag interference with receptor binding is a concern [4, 5].

The mature domains of human, mouse, and rat GDF11 are 100 percent identical in amino acid sequence, permitting the use of a single recombinant preparation across species in preclinical research [5].

2. Abstract

Growth differentiation factor 11 (GDF11, also known as BMP-11) is a 25-kilodalton disulfide-linked homodimeric protein of the TGF-beta superfamily that signals through activin type II receptors and SMAD2/3-dependent transcriptional regulation. The protein was identified in 1999 by McPherron et al. as a close homolog of myostatin (GDF8), with which it shares approximately 90 percent identity in the mature signaling domain [1]. GDF11 is essential for embryonic development, with knockout mice exhibiting homeotic transformations of the axial skeleton, renal agenesis, and perinatal lethality [1, 11].

GDF11 achieved exceptional scientific prominence between 2013 and 2014 when the Wagers and Lee laboratories at Harvard reported that systemic GDF11 levels decline with age and that recombinant GDF11 administration reverses age-related cardiac hypertrophy [12], restores skeletal muscle stem cell function [13], and enhances cerebrovascular remodeling and neurogenesis in aged mice [14]. These findings, published in *Cell and Science*, generated intense public and scientific interest and were widely reported as evidence for a circulating "rejuvenation factor."

The claims were challenged by multiple independent groups beginning in 2015. Eggerman et al. (2015) and Smith et al. (2015) demonstrated that the aptamer-based and antibody-based assays used in the original studies could not reliably discriminate GDF11 from myostatin, and that GDF11 measured by specific assays may increase rather than decrease with age [15, 16]. Furthermore, several groups showed that supraphysiological recombinant GDF11 inhibits skeletal muscle regeneration and causes cachexia, muscle wasting, and premature death in mice [15, 17, 18, 19]. The Wagers laboratory defended its findings with additional data [20], and the controversy has not been definitively resolved. Subsequent studies have continued to report both beneficial and detrimental effects of GDF11 depending on dose, duration, tissue context, and the specificity of the reagents used.

GDF11 has not entered human clinical trials as a therapeutic agent. Sotatercept, an ActRIIA-Fc fusion protein that traps GDF11 along with activin A and myostatin, was approved by the FDA in March 2024 for pulmonary arterial hypertension [21]. This approval represents the first clinical validation of pharmacological modula-

tion of activin/GDF-class signaling, though the therapeutic benefit of sotatercept derives from sequestration of multiple ligands rather than from GDF11 modulation specifically.

This monograph documents the molecular biology, processing, receptor pharmacology, and signaling of GDF11; the discovery history and the parabiosis experiments; the preclinical evidence across cardiac, skeletal muscle, neurological, and oncological domains; the controversy over assay specificity and direction of age-related change; the limited pharmacokinetic data; the reconstitution and handling of research-grade recombinant protein; the adverse-event and safety signal; and a comparative assessment of five related TGF-beta superfamily ligands and modulators.

3. Discovery and Development History

3.1 Identification of GDF11

GDF11 was independently identified in 1999 by two research groups. McPherron, Lawler, and Lee at Johns Hopkins University School of Medicine cloned the mouse and human GDF11 gene by low-stringency hybridization screening of genomic and cDNA libraries, using myostatin as a probe [1]. The same group had identified myostatin (GDF8) two years earlier and recognized GDF11 as its closest paralog. Concurrently, Gamer et al. cloned the same gene, which they designated BMP-11, by PCR amplification of a human genomic library using primers designed from a bovine BMP-related sequence [22]. The dual nomenclature (GDF11 and BMP-11) persists in the literature, though GDF11 is the predominant designation.

3.2 Developmental biology

The initial characterization of GDF11 function came from gene knockout studies. GDF11-null mice exhibit multiple developmental abnormalities including homeotic transformations of the axial skeleton (anterior transformations of vertebral identity, resulting in extra thoracic vertebrae and additional pairs of ribs), renal agenesis or severe dysgenesis, anorectal malformations, and palatal defects [1, 11, 23]. These animals die within 24 hours of birth. The phenotype established GDF11 as essential for anterior-posterior patterning of the axial skeleton, kidney organogenesis, and craniofacial development.

Subsequent studies demonstrated roles for GDF11 in the development of the pancreas (regulation of beta-cell mass and islet morphogenesis), the olfactory epithelium (control of neuronal progenitor proliferation), the retina (regulation of retinal ganglion cell differentiation), and the spinal cord (specification of motor neuron subtypes) [24, 25, 26, 27]. GDF11 is expressed broadly in adult tissues, with highest mRNA levels in the kidney, spleen, and brain [6].

3.3 The parabiosis era (2013 to 2014)

The heterochronic parabiosis experiments that propelled GDF11 into the aging-research spotlight were conducted principally in the laboratories of Amy Wagers (Harvard Department of Stem Cell and Regenerative Biology) and Richard Lee (Brigham and Women's Hospital Division of Cardiovascular Medicine).

Cardiac hypertrophy (2013). Loffredo et al. used an aptamer-based proteomic platform (SomaLogic SOMAscan) to identify circulating factors that change with age in mice. GDF11 emerged as a candidate whose circulating levels appeared to decline with age. The investigators then demonstrated that 30 days of heterochronic parabiosis reversed age-related cardiac hypertrophy in old parabionts, and that daily intraperitoneal injection of recombinant GDF11 (0.1 mg/kg/day for 30 days) recapitulated this effect in unpaired old mice [12]. The study was published in *Cell* and generated widespread attention as evidence for a circulating anti-aging factor.

Skeletal muscle regeneration (2014). Sinha et al. extended the findings to skeletal muscle, reporting that supplementation of systemic GDF11 levels by heterochronic parabiosis or by systemic delivery of recombinant protein reversed functional impairments and restored genomic integrity in aged muscle stem (satellite) cells, increased muscle fiber cross-sectional area, and enhanced exercise capacity in old mice [13]. The study was published in *Science*.

Cerebrovascular and neurogenic rejuvenation (2014). Katsimpardi et al. demonstrated that exposure to young blood through heterochronic parabiosis or systemic GDF11 injection promoted remodeling of the cerebral vasculature, increased subventricular zone neural stem cell numbers, enhanced hippocampal neurogenesis, and improved olfactory discrimination in aged mice [14]. The study was also published in *Science*.

These three publications collectively positioned GDF11 as a pleiotropic circulating rejuvenation factor and were recognized by *Science* as a runner-up for the 2014 Breakthrough of the Year.

3.4 The replication controversy (2015 to present)

The initial claims were challenged on multiple grounds beginning in mid-2015.

Assay specificity. Eggerman et al. (2015) at the Novartis Institutes for Biomedical Research demonstrated that the SomaLogic aptamer used in the Loffredo et al. study exhibited substantial cross-reactivity with myostatin, and that an ELISA assay used in the Sinha et al. study similarly could not discriminate GDF11 from myostatin [15]. When measured by a validated mass spectrometry-based method, GDF11 levels in mouse serum did not decline with age. Smith et al. (2015) at Amgen independently reported that immunoreactivity attributed to GDF11 in aged mouse serum was predominantly myostatin, and that GDF11 levels measured by their assay actually increased with age [16].

Skeletal muscle effects. Eggerman et al. further demonstrated that recombinant GDF11 at doses comparable to those used in the Sinha et al. study inhibited rather than promoted myoblast differentiation in vitro and satellite cell activation in vivo, and that GDF11 overexpression caused muscle atrophy [15]. Multiple subsequent groups confirmed the muscle-inhibitory effects of supraphysiological GDF11 [17, 18, 19].

Cachexia and toxicity. Hammers et al. (2017) and Jones et al. (2018) demonstrated that sustained supraphysiological GDF11 administration causes severe cachexia, with greater than 30 percent body weight loss, skeletal and cardiac muscle wasting, and premature death in mice at the highest tested doses (5.0 mg/kg/day) [18, 19]. The cachexia mechanism involved activation of SMAD2-dependent ubiquitin-proteasome and autophagy pathways in skeletal muscle, and was partially mediated by secondary upregulation of GDF15 [28].

Defense and refinement. The Wagers laboratory defended its findings and published additional studies demonstrating cardiac benefits of GDF11 at lower doses and with carefully characterized recombinant protein [20]. The group acknowledged the assay-specificity issues but argued that the biological effects of recombinant GDF11 in the parabiosis paradigm were reproducible and distinct from those of myostatin. Subsequent investigations by other groups have continued to report both beneficial and detrimental effects depending on dose, route of administration, duration, tissue context, and the age and strain of the experimental animals.

3.5 Current status

As of 2026, GDF11 is not in active clinical development as a therapeutic agent. No recombinant GDF11 preparation has entered human clinical trials. The principal clinical relevance of GDF11-class signaling is through sotatercept, the ActRIIA-Fc

ligand trap approved for pulmonary arterial hypertension [21]. Preclinical investigation of GDF11 continues in the domains of cardiac biology, neurogenesis, stroke recovery, cancer biology, and fundamental aging research. The compound is classified as a research-grade biological for investigational use only.

4. Mechanism of Action

GDF11 signals through a canonical TGF-beta superfamily receptor complex and activates both SMAD-dependent (canonical) and SMAD-independent (non-canonical) intracellular pathways. The signaling mechanism is shared in large part with myostatin and activin A, reflecting the high structural homology among these ligands and their use of overlapping receptor components.

4.1 Receptor engagement

The active GDF11 homodimer binds first to type II serine/threonine kinase receptors, principally activin receptor type IIA (ActRIIA, encoded by ACVR2A) and activin receptor type IIB (ActRIIB, encoded by ACVR2B). Binding to type II receptors recruits type I receptors, principally activin receptor-like kinase 4 (ALK4, encoded by ACVR1B) and activin receptor-like kinase 5 (ALK5, encoded by TGFB1), into a heterotetrameric signaling complex consisting of two type II and two type I receptor molecules bridged by the GDF11 homodimer [29, 30]. The type II receptor phosphorylates the type I receptor in the glycine-serine-rich (GS) domain, activating the type I receptor kinase.

GDF11 has been reported to bind ALK7 (ACVR1C) in certain contexts, though ALK4 and ALK5 are considered the principal signaling type I receptors [30]. GDF11 does not engage BMP-class type I receptors (ALK1, ALK2, ALK3, ALK6) under physiological conditions.

Affinity comparisons indicate that GDF11 is substantially more potent than myostatin at activating SMAD2/3 signaling in cardiac and other cell types, despite the high sequence homology in the mature domain [6, 31]. The potency difference is attributed to subtle differences in receptor-binding affinity and in the stability of the ligand-receptor complex.

4.2 Canonical SMAD signaling

The activated type I receptor (ALK4 or ALK5) phosphorylates the receptor-regulated SMAD proteins SMAD2 and SMAD3 at their C-terminal serine residues. Phosphorylated SMAD2/3 (pSMAD2/3) forms a heterotrimer with the common me-

diator SMAD4, and the complex translocates to the nucleus where it regulates transcription of target genes through direct DNA binding at SMAD-binding elements (SBEs) and through interactions with co-activators and co-repressors [29, 32].

Target genes regulated by the GDF11-SMAD2/3 pathway include genes involved in cell cycle arrest (p15INK4b, p21CIP1), apoptosis, extracellular matrix remodeling, and developmental patterning (Hox gene clusters for axial skeleton specification) [11, 32]. The inhibitory SMAD protein SMAD7 provides negative feedback by competing with SMAD2/3 for receptor binding and by recruiting E3 ubiquitin ligases (SMURF1, SMURF2) that target the type I receptor for proteasomal degradation [32].

4.3 Non-canonical signaling

GDF11 also activates SMAD-independent signaling pathways, though these are less comprehensively characterized than the canonical SMAD pathway. Reported non-canonical pathways include mitogen-activated protein kinase (MAPK) cascades (ERK1/2, p38 MAPK, JNK), phosphatidylinositol 3-kinase (PI3K)/Akt, and nuclear factor kappa-B (NF-kappaB) pathways [33, 34]. The contribution of non-canonical signaling to the biological effects of GDF11 in specific tissue contexts (cardiac, skeletal muscle, neural, oncological) remains an active area of investigation.

4.4 Extracellular regulation

The bioavailability of active GDF11 is tightly regulated by multiple extracellular mechanisms:

Latent complex formation. As described in Section 1.2, the GDF11 prodomain remains non-covalently associated with the mature homodimer after furin cleavage, forming a latent complex that prevents receptor binding. Release of the active homodimer requires tolloid metalloproteinase cleavage of the prodomain [7, 8].

Follistatin and related proteins. Follistatin binds the GDF11 mature domain with high affinity and neutralizes its signaling activity. FSTL3 (also called FLRG) has a similar but not identical binding profile. These proteins provide a circulating buffer that limits free GDF11 bioactivity [9].

WFIKKN proteins. WFIKKN1 and WFIKKN2 (also called GASP1 and GASP2) are multi-domain extracellular proteins that bind and inhibit GDF11 and myostatin. WFIKKN2 has been reported to be a more potent inhibitor of GDF11 than of myostatin in some assays [10].

Receptor decoy and ligand trap. The soluble extracellular domains of ActRIIA and ActRIIB function as endogenous ligand traps. Sotatercept (ActRIIA-Fc) and luspatercept (modified ActRIIB-Fc) are engineered fusion proteins that exploit this mechanism therapeutically [21].

5. Pharmacokinetics

The pharmacokinetics of recombinant GDF11 have been characterized only in pre-clinical (mouse) models. No human pharmacokinetic data exist, as the protein has not entered human clinical trials.

5.1 Route of administration and absorption

Recombinant GDF11 has been administered by intraperitoneal injection in the majority of published mouse studies. The standard research dose range is 0.1 to 1.0 mg/kg/day by daily intraperitoneal injection [12, 13, 14, 15]. Subcutaneous injection has also been used in some protocols. Intravenous administration has been employed in acute pharmacodynamic studies.

Following intraperitoneal injection of recombinant GDF11 at 0.1 mg/kg in mice, circulating GDF11/8 plasma levels increase within 1 to 2 hours, indicating rapid absorption from the peritoneal cavity [35].

5.2 Distribution

Tissue distribution data for exogenously administered recombinant GDF11 are limited. Endogenous GDF11 mRNA is broadly expressed in adult mouse and human tissues, with highest expression in kidney, spleen, brain, and pancreas, and lower expression in skeletal muscle, heart, liver, and adipose tissue [6]. Whether exogenous recombinant GDF11 distributes to these tissues in proportion to endogenous expression is not established.

GDF11 crosses the blood-brain barrier to a sufficient extent to produce central nervous system effects (enhanced neurogenesis, cerebrovascular remodeling) when administered systemically in mice, as demonstrated by the Katsimpardi et al. (2014) studies [14]. Whether this reflects direct protein transit across the blood-brain barrier or indirect signaling through endothelial or immune intermediaries has not been definitively established.

5.3 Metabolism and elimination

The plasma half-life of recombinant GDF11 in mice is approximately 12 hours [35]. Clearance mechanisms have not been fully characterized but are expected to follow the general pattern for TGF-beta superfamily ligands: binding to extracellular inhibitors (follistatin, FSTL3, WFIKKN1/2), receptor-mediated endocytosis and lysosomal degradation, and hepatic and renal clearance of degradation products.

The relatively short half-life necessitates daily or more frequent dosing to maintain elevated circulating levels, as reflected in the daily injection protocols used in the published preclinical literature.

5.4 Dose-response considerations

The dose-response relationship for recombinant GDF11 is narrow and tissue-dependent. At 0.1 mg/kg/day in mice (the standard "rejuvenation" dose used in the original Wagers laboratory studies), reported effects include modest reversal of cardiac hypertrophy and enhancement of neurogenesis without apparent toxicity [12, 14]. At 1.0 mg/kg/day, some studies report anti-hypertrophic cardiac effects, while others report the onset of skeletal muscle wasting [18, 19]. At 5.0 mg/kg/day, severe cachexia, greater than 30 percent body weight loss, and premature death are consistently observed [19].

The narrow therapeutic window, combined with the assay-specificity controversies that complicate interpretation of endogenous circulating levels, represents a significant challenge for translational development.

6. Preclinical Pharmacology

6.1 Cardiac biology

The original Loffredo et al. (2013) study reported that recombinant GDF11 at 0.1 mg/kg/day for 30 days reversed age-related cardiac hypertrophy in old mice, reducing cardiomyocyte cross-sectional area and ventricular wall thickness to levels comparable to young animals [12]. The mechanism was attributed to GDF11-SMAD2/3 signaling in cardiomyocytes, producing anti-hypertrophic gene expression changes.

Subsequent studies produced conflicting results. Smith et al. (2015) found no effect of recombinant GDF11 on cardiac structure or function using an independent protein preparation and more specific assays [16]. Jones et al. (2018) found that GDF11 at 1.0 mg/kg/day reduced pressure-overload-induced cardiac hypertrophy but that higher doses (5.0 mg/kg/day) caused cardiac wasting along with systemic cachexia [19]. The Wagers laboratory provided additional data defending the cardiac anti-hypertrophic effect with carefully validated recombinant protein and proposed that discrepancies were attributable to protein quality, dose, and experimental design differences [20].

The cardiac biology of GDF11 therefore remains contested, with the preponderance of evidence suggesting that modest doses may produce anti-hypertrophic effects while supraphysiological doses cause cardiac and systemic wasting.

6.2 Skeletal muscle

The Sinha et al. (2014) report that recombinant GDF11 restores aged muscle stem cell function and enhances muscle repair [13] was directly contradicted by Eggerman et al. (2015), who showed that GDF11 inhibits myoblast differentiation and satellite cell activation through SMAD2/3-dependent upregulation of muscle atrophy-associated E3 ubiquitin ligases (MuRF1, atrogin-1) [15]. Hammers et al. (2017) confirmed that exogenous GDF11 induces skeletal muscle dysfunction, decreased fiber size, and reduced grip strength through activation of the ubiquitin-proteasome and autophagy pathways [18].

The inhibitory effect of GDF11 on skeletal muscle is mechanistically consistent with the established biology of the activin/myostatin subclass: myostatin, the closest GDF11 paralog, is the canonical negative regulator of skeletal muscle mass, and GDF11 signals through the same receptors to activate the same SMAD2/3-dependent atrophy program [6, 15]. The original Sinha et al. findings are therefore difficult to reconcile with the established receptor pharmacology and have not been independently replicated by groups outside the Wagers laboratory.

6.3 Neurobiology

The neurobiological effects of GDF11 have generated less controversy than the cardiac and skeletal muscle findings. The Katsimpardi et al. (2014) demonstration that systemic GDF11 enhances cerebrovascular remodeling, increases subventricular zone neural stem cell numbers, promotes hippocampal neurogenesis, and improves olfactory discrimination in aged mice [14] has been partially supported by independent groups. Ozek et al. (2018) demonstrated that recombinant GDF11 treatment leads to neuronal and vascular improvements in the hippocampus of aged mice, with increased markers of neuronal activity and plasticity [36].

However, a competing body of evidence suggests more complex effects. Mayweather et al. (2021) showed that GDF11 expressed endogenously in the adult brain negatively regulates hippocampal neurogenesis, suggesting that the exogenous administration paradigm may produce different effects than endogenous GDF11 signaling [37]. Zhang et al. (2023) reported that systemic GDF11 attenuates depression-like phenotype in aged mice through stimulation of neuronal autophagy, providing an additional mechanism beyond the originally proposed vascular remodeling [38].

The neurobiological evidence therefore supports beneficial central nervous system effects of systemic GDF11 administration in aged animals, though the mechanisms are likely more complex than the simple "rejuvenation" narrative originally proposed.

6.4 Stroke recovery

Recombinant GDF11 has shown promise in preclinical stroke models. Lu et al. (2018) demonstrated that systemic GDF11 administration promotes recovery in a rat permanent ischemia model of subacute stroke, with improved neurological

function and increased angiogenesis and neurogenesis in the peri-infarct region [39]. These findings are consistent with the pro-angiogenic and neurogenic properties described in the aging literature and suggest a potential application distinct from the age-reversal paradigm.

6.5 Cancer biology

GDF11 exhibits tissue-dependent effects in cancer models. In hepatocellular carcinoma, GDF11 has tumor-suppressive properties: it restricts spheroid formation, decreases proliferation, inhibits invasion and migration, promotes apoptosis, and may sensitize resistant cancer cells to chemotherapy [40, 41]. In pancreatic cancer, GDF11 overexpression similarly restrains tumor growth through promotion of apoptosis, with high GDF11 expression serving as an independent predictor of favorable prognosis [42].

However, in colorectal cancer, GDF11 expression is elevated in tumor tissue compared to normal tissue, and high GDF11 levels are associated with increased lymph node metastasis and reduced survival [43]. This opposing pattern underscores the context-dependence of GDF11 biology and argues against a simple characterization of GDF11 as uniformly beneficial or detrimental in cancer.

6.6 Erythropoiesis

GDF11 is a negative regulator of terminal erythroid differentiation. Excessive GDF11 signaling suppresses erythropoiesis by promoting growth arrest and apoptosis in late-stage erythroid progenitors [44]. This biology is clinically relevant because the therapeutic benefit of luspatercept (a modified ActRIIB-Fc ligand trap approved for transfusion-dependent anemias in myelodysplastic syndromes and beta-thalassemia) derives in substantial part from neutralization of GDF11-mediated erythropoietic suppression [45].

7. Clinical Evidence Base

7.1 Direct GDF11 clinical trials

No recombinant GDF11 preparation has entered human clinical trials as of the date of this monograph. The translational path from preclinical findings to clinical investigation has been impeded by the replication controversy, the narrow therapeutic window, the assay-specificity issues that complicate biomarker-guided dosing, and the absence of a pharmaceutical sponsor with sufficient confidence in the risk-benefit profile to support an investigational new drug application.

7.2 Indirect clinical relevance through ligand traps

The principal clinical relevance of GDF11-class signaling is through ActRII-Fc fusion proteins that sequester GDF11 along with related ligands.

Sotatercept (ActRIIA-Fc, Winrevair). Sotatercept is a fusion protein consisting of the extracellular domain of human ActRIIA linked to the Fc domain of human IgG1. It binds and neutralizes activin A, GDF11, GDF8 (myostatin), and BMP10. Sotatercept was approved by the FDA in March 2024 for the treatment of pulmonary arterial hypertension based on the STELLAR Phase 3 trial, which demonstrated significant improvements in six-minute walk distance, pulmonary vascular resistance, and NT-proBNP levels [21, 46]. The mechanism of benefit in pulmonary arterial hypertension is attributed to rebalancing of proliferative (SMAD2/3) and anti-proliferative (SMAD1/5/8) signaling in the pulmonary vasculature, with sequestration of activin A as the principal driver. The contribution of GDF11 neutralization to the therapeutic effect is not specifically delineated.

Luspatercept (modified ActRIIB-Fc, Reblozyl). Luspatercept is a modified ActRIIB-Fc fusion protein approved for transfusion-dependent anemias in myelodysplastic syndromes and beta-thalassemia. Its mechanism involves neutralization of GDF11 and other activin-class ligands that suppress terminal erythroid differentiation [45].

7.3 Epidemiological associations

Several epidemiological studies have examined associations between circulating GDF11 levels and clinical outcomes in humans, though interpretation is complicated by the assay cross-reactivity with myostatin discussed above. Elevated GDF11/8 immunoreactivity has been associated with frailty, sarcopenia, and adverse cardiovascular outcomes in some cohorts, while other studies report inverse associations [47]. The conflicting directions of association in human epidemiological data mirror the preclinical controversy and underscore the need for validated, myostatin-discriminating assays before circulating GDF11 can be used as a clinical biomarker.

8. Sourcing and Quality Verification

Recombinant GDF11 is available from multiple commercial suppliers of research-grade biological reagents. The principal sources include:

- R&D Systems / Bio-Techne (catalog 1958-GD): recombinant human/mouse/rat GDF11, E. coli-expressed, untagged, greater than 95 percent purity by SDS-PAGE.
- PeproTech / Thermo Fisher (catalog 120-11): recombinant human/mouse/rat GDF11, E. coli-expressed, greater than 98 percent purity by SDS-PAGE.
- ProSpec (catalog CYT-299 and CYT-896): recombinant human GDF11, E. coli-expressed, untagged and His-tagged variants.
- Cell Signaling Technology (catalog 86907): recombinant human/mouse/rat GDF11.
- Sino Biological, Cusabio, NovoPro, and multiple additional suppliers.

Pricing is in the range of \$200 to \$500 per 10 micrograms for high-purity untagged recombinant protein, and \$50 to \$200 per 10 micrograms for tagged variants, at the time of monograph preparation.

Quality verification. The replication controversy has highlighted the critical importance of protein quality verification for GDF11 research. Quality control studies conducted during the controversy found that commercial preparations of GDF11 varied substantially in protein quantity, purity, activity, and contamination with related ligands [20]. Investigators should confirm:

- Purity by SDS-PAGE (reducing and non-reducing conditions) to verify homodimer formation and the absence of degradation products.
- Biological activity by a validated cell-based reporter assay (SMAD2/3-responsive luciferase or similar), with comparison to a reference standard.
- Protein identity by mass spectrometry to confirm the expected molecular mass and to exclude contamination with myostatin, activin A, or other TGF-beta superfamily ligands.
- Endotoxin content by Limulus amoebocyte lysate (LAL) assay, targeting less than 1 EU per microgram for in vivo studies.

- Absence of myostatin cross-contamination, ideally confirmed by a validated assay capable of distinguishing GDF11 from GDF8.

Third-party analytical verification is recommended for any investigation where dose-response precision or mechanism-of-action specificity is important, given the documented lot-to-lot variability in commercial preparations.

9. Reconstitution and Handling

Recombinant GDF11 is supplied as a lyophilized powder, typically from a solution containing a carrier buffer (commonly phosphate-buffered saline with or without trehalose or mannitol as a cryoprotectant). Handling recommendations follow the general pattern for TGF-beta superfamily recombinant proteins.

Reconstitution. Reconstitute lyophilized GDF11 in sterile water or sterile phosphate-buffered saline at a concentration of not less than 0.1 mg/mL [4, 5]. Do not vortex; mix by gentle swirling or pipetting to avoid protein denaturation. For in vitro applications requiring higher stock concentrations, reconstitution in 4 mM hydrochloric acid (a standard acidic reconstitution buffer for TGF-beta superfamily proteins) at up to 1 mg/mL may be used.

Carrier protein. For dilute working solutions and for long-term storage of reconstituted protein, the addition of a carrier protein (0.1 percent bovine serum albumin [BSA] or 0.1 percent human serum albumin [HSA]) is recommended to prevent adsorption to container surfaces and to enhance protein stability [4].

Storage of lyophilized material. Store desiccated at minus 20 to minus 80 degrees Celsius. Lyophilized GDF11 is stable for up to 12 months at minus 80 degrees Celsius. The powder is stable at room temperature for approximately 3 weeks but long-term room-temperature storage is not recommended.

Storage of reconstituted material. Reconstituted GDF11 should be used within 2 to 7 days if stored at 2 to 8 degrees Celsius. For longer storage, prepare single-use aliquots and store at minus 20 degrees Celsius or below; aliquots are stable for approximately 3 months. Avoid repeated freeze-thaw cycles, which can reduce protein activity.

Biological activity verification. Given the documented variability in commercial preparations, investigators should verify biological activity of each lot before use in functional experiments. A SMAD2/3 phosphorylation assay in a responsive cell line (A204 rhabdomyosarcoma cells or HEK293T cells expressing a SMAD2/3-responsive reporter) provides a practical functional quality check.

10. Stack Interactions and Combinations

GDF11 is a research-grade biological that is studied in the context of TGF-beta superfamily signaling. Interactions relevant to the research setting include:

Myostatin (GDF8). GDF11 and myostatin signal through the same receptors and activate the same SMAD2/3 pathway. Concurrent administration produces additive or synergistic activation of the canonical pathway and additive suppression of muscle mass and erythropoiesis [6, 15]. The combination amplifies the risk of cachexia and muscle wasting and is not recommended in preclinical research without specific mechanistic justification.

Activin A. Activin A shares receptor utilization with GDF11 (ActRIIA/B, ALK4) and activates SMAD2/3. Supraphysiological GDF11 has been shown to elicit secondary elevation of circulating activin A, which contributes to the cachexia phenotype [28]. The interaction suggests that exogenous GDF11 may amplify endogenous activin A signaling, compounding the muscle-wasting signal.

Follistatin. Follistatin neutralizes GDF11 bioactivity by direct binding. Concurrent administration of follistatin with GDF11 would be expected to attenuate GDF11 signaling and could serve as a rescue intervention in toxicity models. Follistatin overexpression produces the muscle-hypertrophy phenotype opposite to GDF11/myostatin administration and has been studied as a counter-regulatory agent [9].

ActRII-Fc ligand traps (sotatercept, luspatercept). These engineered fusion proteins sequester GDF11 along with related ligands. Concurrent administration of recombinant GDF11 with an ActRII-Fc ligand trap would be pharmacologically antagonistic and is relevant principally as a tool for dissecting the contribution of GDF11 to composite ligand-trap effects.

BMP ligands (BMP2, BMP7, BMP9). BMP-class ligands signal through SMAD1/5/8 rather than SMAD2/3 and generally produce opposing biological effects to GDF11 in the cardiovascular, skeletal muscle, and erythropoietic compartments [21, 46]. The balance between SMAD2/3 (GDF11/activin) and SMAD1/5/8 (BMP) signaling is the

molecular basis for the therapeutic mechanism of sotatercept in pulmonary arterial hypertension. Concurrent administration of GDF11 with BMP ligands could be a productive research paradigm for investigating this signaling balance.

Erythropoiesis-stimulating agents (EPO, darbepoetin). GDF11 suppresses terminal erythroid differentiation; EPO promotes it. The interaction is clinically relevant in the context of luspatercept therapy for anemias, where GDF11 neutralization enhances the erythropoietic response to endogenous and exogenous EPO [45].

11. Adverse Events and Safety Signal

11.1 Preclinical toxicity

GDF11 exhibits a narrow therapeutic window with dose-dependent toxicity that has been consistently demonstrated across multiple independent laboratories.

Cachexia. The most severe adverse effect of supraphysiological GDF11 administration is systemic cachexia. Jones et al. (2018) demonstrated that recombinant GDF11 at 5.0 mg/kg/day in mice causes greater than 30 percent body weight loss within 9 days, with severe skeletal muscle wasting, cardiac muscle wasting, adipose tissue loss, and organ atrophy, leading to death or necessitating euthanasia [19]. At 1.0 mg/kg/day, more modest but measurable body weight loss and muscle wasting were observed. The mechanism involves SMAD2-dependent activation of the ubiquitin-proteasome and autophagy-lysosome protein degradation pathways in skeletal muscle, producing accelerated myofibrillar protein breakdown [18, 19].

Secondary GDF15 elevation. Patel et al. (2018) demonstrated that supraphysiological GDF11 administration causes a significant elevation of circulating GDF15, a distinct TGF-beta superfamily member that is an established mediator of cancer-associated anorexia and cachexia [28]. The secondary GDF15 elevation contributes to the reduced food intake and weight loss observed with high-dose GDF11.

Skeletal muscle dysfunction. Hammers et al. (2017) showed that exogenous GDF11 at doses within the published "rejuvenation" range (0.1 to 0.5 mg/kg/day) produces detectable skeletal muscle changes by day 13, including decreased fiber size, reduced grip strength, and activation of atrophy-associated signaling pathways [18].

Erythropoietic suppression. GDF11 suppresses terminal erythroid differentiation through SMAD2/3-dependent growth arrest and apoptosis in late-stage erythroid progenitors [44]. Chronic supraphysiological GDF11 would be expected to produce anemia, though this endpoint has not been systematically characterized in the published toxicity studies.

11.2 Dose-dependent risk stratification

Based on the published preclinical literature, the following dose-risk framework can be constructed for recombinant GDF11 administered by daily intraperitoneal injection in mice:

- 0.1 mg/kg/day: reported "rejuvenation" dose. Cardiac anti-hypertrophic and neurogenic effects reported by the Wagers laboratory; no overt toxicity in most published protocols of 30 days duration. However, subclinical skeletal muscle effects cannot be excluded at this dose based on the Hammers et al. (2017) data.
- 0.5 to 1.0 mg/kg/day: intermediate dose range. Some reports of anti-hypertrophic cardiac effects; onset of measurable skeletal muscle wasting, decreased fiber size, and reduced strength in multiple independent studies.
- 5.0 mg/kg/day: frankly toxic. Severe cachexia, organ wasting, and premature death within 9 to 14 days.

11.3 Human safety data

No human safety data exist for recombinant GDF11. Human safety data for the pharmacological modulation of GDF11-class signaling exist only in the context of ActRII-Fc ligand traps (sotatercept, luspatercept), where GDF11 neutralization is one component of a multi-ligand mechanism. The adverse-event profile of sotatercept (thrombocytopenia, bleeding events, telangiectasia, erythrocytosis) reflects the composite pharmacology of multi-ligand trapping and cannot be attributed specifically to GDF11 modulation [21, 46].

11.4 Considerations for research use

Investigators using recombinant GDF11 in preclinical research should:

- Use validated, myostatin-discriminating assays to monitor circulating GDF11 levels and to confirm that the administered dose produces the intended pharmacodynamic effect.
- Monitor body weight, food intake, and grip strength as sensitive early indicators of the cachexia and muscle-wasting signal.
- Use the lowest effective dose, with awareness that the 0.1 mg/kg/day "rejuvenation" dose is at the lower boundary of the detectable effect range and that mod-

est dose escalation rapidly approaches the toxicity threshold.

- Exercise particular caution in aged animals, which may be more susceptible to the catabolic effects of SMAD2/3 activation in skeletal muscle.

12. Comparative Assessment

This section presents a structured comparative assessment of five related TGF-beta superfamily ligands and modulators against GDF11, evaluated on five standards: novelty, effect size, promising potential (current research and development trajectory), side-effect profile (preclinical or clinical), and overall validation. The five comparators were selected to represent the principal members of the activin/myostatin ligand subclass and the key pharmacological modulators of GDF11-class signaling.

12.1 Myostatin (GDF8, MSTN)

Mechanism: Myostatin is a homodimeric TGF-beta superfamily ligand that signals through ActRIIA/B and ALK4/ALK5 to activate SMAD2/3, identical to the GDF11 receptor complex. Myostatin is the canonical negative regulator of skeletal muscle mass; loss-of-function mutations in myostatin produce the double-muscling phenotype in cattle and increased muscle mass in mice and humans [48].

Novelty: Low. Myostatin was identified in 1997, two years before GDF11, and is the most extensively characterized member of the activin/myostatin subclass. Its biology is well established.

Effect size: Substantial in the muscle-hypertrophy domain. Myostatin inhibition by antibodies (domagrozumab, stamulumab), ligand traps (bimagrumab targeting ActRIIA/B), or gene-based approaches produces large increases in skeletal muscle mass in animal models [48]. Clinical effect sizes on functional endpoints (strength, six-minute walk distance) have been modest in human trials, and no myostatin inhibitor has achieved regulatory approval for a primary muscle-wasting indication.

Promising potential: Moderate. Multiple myostatin-targeting therapeutics have been tested in clinical trials for muscular dystrophy, sarcopenia, and cachexia without regulatory approval. The approach remains under investigation.

Side-effect profile: Myostatin inhibition is generally well tolerated, with the principal concern being off-target effects on cardiac and metabolic pathways. Exogenous myostatin administration produces effects similar to GDF11: muscle atrophy and cachexia at supraphysiological doses.

Overall validation: High as a biological concept; moderate as a therapeutic approach. Myostatin is one of the most validated targets in muscle biology but has not yet yielded an approved therapeutic.

Comparison to GDF11: GDF11 and myostatin share 90 percent mature-domain identity and signal through the same receptors. The key distinction is tissue expression pattern: myostatin is predominantly expressed in skeletal and cardiac muscle, whereas GDF11 is broadly expressed across tissues. GDF11 is reported to be more potent than myostatin at activating SMAD2/3 in cardiac cells [31]. The overlapping biology is the source of both the assay cross-reactivity controversy and the difficulty in dissecting the individual contributions of each ligand in physiological and pathological contexts.

12.2 Activin A

Mechanism: Activin A is a homodimeric or heterodimeric TGF-beta superfamily ligand (composed of inhibin betaA subunits) that signals through ActRIIA/B and ALK4 to activate SMAD2/3. It plays essential roles in reproductive physiology, inflammation, fibrosis, and erythropoiesis [49].

Novelty: Low. Activin A was identified in the 1980s and is one of the founding members of the TGF-beta superfamily. Its biology is extensively characterized.

Effect size: Substantial in the erythropoietic suppression domain and in pulmonary vascular remodeling. Activin A is considered the principal pathogenic ligand in the SMAD2/3-overactivation phenotype that drives pulmonary arterial hypertension and ineffective erythropoiesis in myelodysplastic syndromes [21, 45].

Promising potential: High (as a therapeutic target). Sotatercept (which traps activin A along with GDF11 and myostatin) was approved for PAH in 2024; luspatercept (which traps GDF11 and activin-class ligands) is approved for anemias. Activin A neutralization is the principal driver of benefit in both programs.

Side-effect profile: Activin A overexpression produces cachexia and muscle wasting similar to GDF11 and myostatin. Therapeutic neutralization of activin A is associated with thrombocytopenia and bleeding in clinical trials of sotatercept [21].

Overall validation: Very high as a therapeutic target; two approved drugs (sotatercept, luspatercept) function in substantial part through activin A neutralization.

Comparison to GDF11: GDF11 and activin A share receptor utilization and SMAD2/3 signaling but are structurally distinct (different ligand subclasses within the superfamily). Activin A is better validated as a therapeutic target, with two approved drugs that neutralize it. The relative contribution of GDF11 versus activin A to the therapeutic benefit of sotatercept and luspatercept is not delineated, but activin A is generally considered the principal target. GDF11 contributes to the erythropoietic suppression that luspatercept addresses [45].

12.3 BMP9 (GDF2)

Mechanism: BMP9 (also designated GDF2) is a BMP-class TGF-beta superfamily ligand that signals through ALK1 and ActRIIA/B to activate SMAD1/5/8, the opposing branch of TGF-beta superfamily signaling relative to GDF11 [50]. BMP9 is produced principally by the liver and circulates at high concentrations in plasma. It is a potent regulator of vascular homeostasis and endothelial quiescence.

Novelty: Moderate. BMP9 biology has been extensively characterized in the vascular and hematopoietic fields, but its role as the physiological counterbalance to activin/GDF11 signaling in pulmonary vasculature is a more recent insight.

Effect size: Substantial in vascular biology. BMP9/SMAD1/5/8 signaling promotes endothelial quiescence and suppresses pathological vascular remodeling. Loss-of-function mutations in BMP9 (GDF2) are a cause of hereditary hemorrhagic telangiectasia and are associated with pulmonary arterial hypertension [50].

Promising potential: Moderate. Recombinant BMP9 has been investigated in pre-clinical models of pulmonary hypertension and vascular disease. Clinical development is early-stage.

Side-effect profile: Preclinical only. BMP9 overexpression promotes ectopic calcification in some contexts.

Overall validation: Moderate as a therapeutic candidate; high as a biological concept in vascular homeostasis.

Comparison to GDF11: BMP9 and GDF11 represent opposing arms of TGF-beta superfamily signaling: GDF11 activates SMAD2/3 (proliferative, pro-remodeling), while BMP9 activates SMAD1/5/8 (anti-proliferative, quiescence-promoting). The balance between these two signaling branches is the molecular basis for sotater-

cept efficacy in PAH [21]. Concurrent investigation of GDF11 and BMP9 provides a framework for understanding TGF-beta superfamily signaling balance in cardiovascular, pulmonary, and aging biology.

12.4 Follistatin (FST)

Mechanism: Follistatin is not a signaling ligand but a secreted glycoprotein that functions as an extracellular antagonist by binding and neutralizing GDF11, myostatin, activin A, and several other TGF-beta superfamily ligands with high affinity [9]. Follistatin sequesters these ligands and prevents their engagement with cell-surface receptors.

Novelty: Low. Follistatin was identified in the 1980s as an activin-binding protein in ovarian follicular fluid.

Effect size: Substantial. Follistatin overexpression produces a dramatic muscle-hypertrophy phenotype (the opposite of GDF11/myostatin signaling) and has been shown to rescue muscle wasting in preclinical models of muscular dystrophy and sarcopenia [51]. Follistatin gene therapy (using AAV vectors) has been tested in human clinical trials for inclusion body myositis and Becker muscular dystrophy, with modest but detectable improvements in functional endpoints [52].

Promising potential: Moderate. Clinical development of follistatin-based therapies is in early to mid stages. Gene therapy approaches face the standard delivery and immunogenicity challenges of the AAV platform.

Side-effect profile: Follistatin overexpression may suppress reproductive function (through activin neutralization) and could theoretically promote tumor growth by relieving TGF-beta superfamily growth inhibition. Clinical safety data from gene therapy trials are limited but have not identified serious safety signals.

Overall validation: Moderate as a therapeutic approach; high as a research tool for dissecting GDF11/myostatin/activin biology.

Comparison to GDF11: Follistatin is the principal endogenous antagonist of GDF11. The follistatin-GDF11 axis represents a natural regulatory circuit that controls the bioavailability of active GDF11 in the extracellular compartment. Investigators studying GDF11 biology should consider follistatin as both a tool compound (for neutralization experiments) and a potential confounder (endogenous follistatin levels modulate the effective GDF11 signal).

12.5 Sotatercept (ActRIIA-Fc, Winrevair)

Mechanism: Sotatercept is an engineered fusion protein consisting of the extracellular domain of human ActRIIA linked to the Fc domain of human IgG1. It functions as a ligand trap, binding and neutralizing activin A, GDF11, GDF8, and BMP10 in the extracellular compartment [21, 46].

Novelty: High as a therapeutic concept. Sotatercept represents the first approved drug that pharmacologically modulates the activin/GDF/BMP signaling balance, and the first approved ActRII-Fc ligand trap.

Effect size: Substantial. In the STELLAR Phase 3 trial, sotatercept added to background PAH therapy produced a mean improvement of 40.8 meters in six-minute walk distance, significant reductions in pulmonary vascular resistance (234 dyn.s.cm⁻⁵), and significant reductions in NT-proBNP, with a favorable composite clinical deterioration endpoint [46].

Promising potential: Very high. Sotatercept was approved by the FDA in March 2024 and by the EMA subsequently. Ongoing Phase 3 trials (HYPERION, ZENITH, MOONBEAM) are expanding the PAH indication to newly diagnosed and pediatric populations. Investigation in other indications (heart failure, fibrosis) is in early stages.

Side-effect profile: The principal adverse events in clinical trials include thrombocytopenia, telangiectasia, erythrocytosis, diarrhea, and bleeding events. These reflect the composite pharmacology of multi-ligand trapping and cannot be attributed specifically to GDF11 modulation [21, 46].

Overall validation: Very high. FDA-approved with robust Phase 3 efficacy data. The most clinically advanced pharmacological intervention in the GDF11/activin/BMP signaling space.

Comparison to GDF11: Sotatercept neutralizes GDF11 as one of several ligands, and the GDF11-specific contribution to its therapeutic benefit is not delineated. The clinical success of sotatercept validates the broader concept of pharmacological modulation of activin/GDF signaling but does not directly validate GDF11 as a standalone therapeutic target. For investigators studying GDF11 biology, sotatercept serves as a reference pharmacological tool for multi-ligand neutralization and as clinical proof of concept for the signaling pathway.

12.6 Comparator summary

The five comparators occupy distinct positions in the GDF11 signaling ecosystem. **Myostatin** is the closest structural and functional paralog, sharing receptors and downstream signaling, and is the principal source of assay cross-reactivity that has complicated GDF11 research. **Activin A** is the best-validated therapeutic target in the pathway, with two approved drugs functioning through its neutralization. **BMP9** represents the opposing signaling arm and is the molecular counterbalance to GDF11-class signaling in vascular and hematopoietic biology. **Follistatin** is the principal endogenous antagonist and a versatile research tool. **Sotatercept** is the most clinically advanced intervention, providing the first regulatory validation of pharmacological modulation of GDF11-class signaling.

GDF11 occupies a unique but contested position in this landscape. It is the only member of the panel that has been proposed as a directly beneficial circulating factor whose administration (rather than neutralization) could produce therapeutic effects. This positioning is in tension with the established biology of the activin/myostatin subclass, where all other well-characterized members function as negative regulators whose inhibition (not augmentation) is therapeutically desirable. The resolution of this tension requires continued investigation with rigorously validated reagents and assays, carefully controlled dose-response studies, and transparent reporting of both beneficial and adverse effects.

The principal practical question for GDF11 research is whether there exists a dose and duration of recombinant GDF11 administration that produces net beneficial effects (cardiac, neurological, vascular) without triggering the cachexia, muscle-wasting, and erythropoietic-suppression toxicity that is predicted by the established receptor pharmacology and confirmed by multiple independent toxicity studies. The available evidence suggests that such a window, if it exists, is extremely narrow and may be tissue- and context-dependent.

13. References

1. McPherron AC, Lawler AM, Lee SJ. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. *Nat Genet.* 1999;22(3):260-264.
2. Walker RG, Poggioli T, Katsimpardi L, et al. Biochemistry and biology of GDF11 and myostatin: similarities, differences, and questions for future investigation. *Circ Res.* 2016;118(7):1125-1142.
3. Ge G, Hopkins DR, Ho WB, Bhola D, Greenspan DS. GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. *Mol Cell Biol.* 2005;25(14):5846-5858.
4. ProSpec. GDF11 Human Recombinant. Protein product specification sheet. CYT-299.
5. R&D Systems. Recombinant Human/Mouse/Rat GDF-11/BMP-11 Protein. Product data sheet. 1958-GD.
6. Walker RG, Czepnik M, Goebel EJ, et al. Structural basis for potency differences between GDF8 and GDF11. *BMC Biol.* 2017;15(1):19.
7. Ge G, Greenspan DS. BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. *J Cell Biol.* 2006;175(1):111-120.
8. Wolfman NM, McPherron AC, Pappano WN, et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. *Proc Natl Acad Sci USA.* 2003;100(26):15842-15846.
9. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. *Proc Natl Acad Sci USA.* 2001;98(16):9306-9311.
10. Monestier O, Brun C, Heu K, et al. Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype. *BMC Genomics.* 2012;13:541.
11. McPherron AC, Huynh TV, Lee SJ. Redundancy of myostatin and growth/differentiation factor 11 function. *BMC Dev Biol.* 2009;9:24.

12. Loffredo FS, Steinhauser ML, Jay SM, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. *Cell*. 2013;153(4):828-839.
13. Sinha M, Jang YC, Oh J, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. *Science*. 2014;344(6184):649-652.
14. Katsimpardi L, Litterman NK, Schein PA, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. *Science*. 2014;344(6184):630-634.
15. Eggerman MA, Cadena SM, Gilbert JA, et al. GDF11 increases with age and inhibits skeletal muscle regeneration. *Cell Metab*. 2015;22(1):164-174.
16. Smith SC, Zhang X, Zhang X, et al. GDF11 does not rescue aging-related pathological hypertrophy. *Circ Res*. 2015;117(11):926-932.
17. Harper SC, Brber A, Schaeffer S, et al. Is growth differentiation factor 11 a realistic therapeutic for aging-dependent muscle defects? *Circ Res*. 2016;118(7):1143-1150.
18. Hammers DW, Merscham-Banda M, Hsiao JY, Engst S, Hartner JC, Sweeney HL. Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting. *Basic Res Cardiol*. 2017;112(4):48.
19. Jones JE, Cadena SM, Gong C, et al. GDF11 decreases pressure overload-induced hypertrophy, but can cause severe cachexia and premature death. *Circ Res*. 2018;123(11):1220-1231.
20. Poggioli T, Vujic A, Yang P, et al. Circulating growth differentiation factor 11/8 levels decline with age. *Circ Res*. 2016;118(1):29-37.
21. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2023;389(16):1446-1457.
22. Gamer LW, Wolfman NM, Celeste AJ, et al. A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in *Xenopus* embryos. *Dev Biol*. 1999;208(1):222-232.
23. Oh SP, Yeo CY, Lee Y, Schrewe H, Whitman M, Li E. Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. *Genes Dev*. 2002;16(21):2749-2754.

24. Harmon EB, Apelqvist AA, Smart NG, Gu X, Osborne DH, Kim SK. GDF11 modulates NGN3+ islet progenitor cell number and promotes beta-cell differentiation in pancreas development. *Development*. 2004;131(24):6163-6174.
25. Wu HH, Ivkovic S, Murray RC, et al. Autoregulation of neurogenesis by GDF11. *Neuron*. 2003;37(2):197-207.
26. Kim J, Wu HH, Lander AD, Lyons KM, Matzuk MM, Calof AL. GDF11 controls the timing of progenitor cell competence in developing retina. *Science*. 2005;308(5730):1927-1930.
27. Liu JP. The function of growth/differentiation factor 11 (Gdf11) in rostrocaudal patterning of the developing spinal cord. *Development*. 2006;133(15):2865-2874.
28. Patel S, Alvarez-Guaita A, Engber TM, et al. Supraphysiologic administration of GDF11 induces cachexia in part by upregulating GDF15. *Cell Rep*. 2018;22(6):1522-1530.
29. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell*. 2003;113(6):685-700.
30. Andersson O, Reissmann E, Ibanez CF. Growth differentiation factor 11 signals through the transforming growth factor-beta receptor ALK5 to regionalize the anterior-posterior axis. *EMBO Rep*. 2006;7(8):831-837.
31. Schafer MJ, Atkinson EJ, Vanderboom PM, et al. Quantification of GDF11 and myostatin in human aging and cardiovascular disease. *Cell Metab*. 2016;23(6):1207-1215.
32. Massague J, Seoane J, Wotton D. Smad transcription factors. *Genes Dev*. 2005;19(23):2783-2810.
33. Zhang YH, Cheng F, Du XT, et al. GDF11/BMP11 as a novel tumor marker for liver cancer. *Exp Ther Med*. 2018;15(4):3495-3500.
34. Liu Y, Shao L, Chen K, Wang Z, Wang J, Jing W. GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer. *Onco Targets Ther*. 2018;11:8855-8863.
35. Katsimpardi L, Kuperwasser N, Camus C, et al. Systemic GDF11 stimulates the secretion of adiponectin and induces a calorie restriction-like phenotype in aged mice. *Aging Cell*. 2020;19(1):e13038.

36. Ozek C, Krolewski RC, Bhola D, et al. Growth differentiation factor 11 treatment leads to neuronal and vascular improvements in the hippocampus of aged mice. *Sci Rep*. 2018;8(1):17293.
37. Mayweather BA, Buchanan SM, Rubin LL. GDF11 expressed in the adult brain negatively regulates hippocampal neurogenesis. *Mol Brain*. 2021;14(1):134.
38. Zhang W, Guo Y, Li B, et al. Systemic GDF11 attenuates depression-like phenotype in aged mice via stimulation of neuronal autophagy. *Nat Aging*. 2023;3(5):550-568.
39. Lu L, Bai X, Cao Y, et al. Growth differentiation factor 11 promotes neurovascular recovery after stroke in mice. *Brain Behav*. 2018;8(5):e00957.
40. Gerardo-Ramirez M, Lazzarini-Lechuga R, Hernandez-Rizo S, et al. GDF11 exhibits tumor suppressive properties in hepatocellular carcinoma cells by restricting clonal expansion and invasion. *Biochim Biophys Acta Mol Basis Dis*. 2019;1865(6):1540-1554.
41. Ma Y, Liu Y, Han F, et al. GDF11 inhibits the malignant progression of hepatocellular carcinoma. *Exp Ther Med*. 2024;27(3):120.
42. Liu Y, Shao L, Chen K, Wang Z, Wang J, Jing W. GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer. *Onco Targets Ther*. 2018;11:8855-8864.
43. Yokoe T, Ohmachi T, Inoue H, et al. Clinical significance of growth differentiation factor 11 in colorectal cancer. *Int J Oncol*. 2007;31(5):1097-1101.
44. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. *Nat Med*. 2014;20(4):408-414.
45. Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. *Lancet Oncol*. 2017;18(10):1338-1347.
46. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. *N Engl J Med*. 2023;388(16):1478-1490.

47. Olson KA, Beatty AL, Heidecker B, et al. Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts. *Eur Heart J*. 2015;36(48):3426-3434.
48. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature*. 1997;387(6628):83-90.
49. Namwanje M, Brown CW. Activins and inhibins: roles in development, physiology, and disease. *Cold Spring Harb Perspect Biol*. 2016;8(7):a021881.
50. Nikolic I, Yung LM, Yang P, et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension. *Am J Respir Crit Care Med*. 2019;199(7):891-902.
51. Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. *Muscle Nerve*. 2009;39(3):283-296.
52. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. *Mol Ther*. 2015;23(1):192-201.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. GDF11 is not approved as a therapeutic agent by any regulatory authority. The compound is supplied as a research-grade recombinant protein for in vitro and preclinical investigation. The replication controversy surrounding the anti-aging claims for GDF11 is unresolved; investigators should design studies with appropriate controls, validated reagents, and awareness of the documented dose-dependent toxicity. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly.